Details of Drug

Drug General Information (ID: D1382)
Drug Name	Ranitidine (bismuth citrate)
Drug Type	Small molecule
Drug Synonymous	Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine Click to Show/Hide
Disease Class	DA61: Peptic ulcer
Therapeutic Class	Antiulcer Agents
Structure
Structure	3D Structure		2D Structure
Formula	C13H22N4O3S
InChI	1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
InChIKey	VMXUWOKSQNHOCA-UKTHLTGXSA-N
Canonical SMILES	CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
External Link
	Pubchem ID	3001055
	CAS Number	82530-72-1
	CHEBI ID	8776
	TTD ID	D0B8WN
	INTEDE ID	DR1393
	VARIDT ID	DR00163

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM003 Complex formation BM005 Altered gastric pH BM010 Transporter inhibition BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM028 Competitive inhibition of renal tubular secretion BM049 Increased risk of atrioventricular block BM051 Increased risk of bradycardia BM055 Increased risk of hepatotoxicity BM081 Increased risk of ventricular arrhythmias BM095 Antagonize the effect of neuromuscular blocking agents
Relation Graph

Full list of drugs interacting with Ranitidine (bismuth citrate)
Affected gastrointestinal absorption
	Complex formation					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0441		Demeclocycline	C21H21ClN2O8	54680690	Moderate		Inter Info	[22], [23], [24]
D0530		Doxycycline	C22H24N2O8	54671203	Moderate		Inter Info	[22], [23], [24]
D1070		Minocycline	C23H27N3O7	54675783	Moderate		Inter Info	[22], [23], [24]
D1175		Omadacycline	C29H40N4O7	54697325	Moderate		Inter Info	[22], [23], [24]
D1445		Sarecycline	C24H29N3O8	54681908	Moderate		Inter Info	[22], [23], [24]
D1564		Tetracycline	C22H24N2O8	54675776	Moderate		Inter Info	[22], [23], [24]
	Altered gastric pH					Drug Num: 43
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[4], [5], [6]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Major		Inter Info	[7], [8]
D1124		Neratinib	C30H29ClN6O3	9915743	Major		Inter Info	[7], [9]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[10], [11], [12]
D1404		Rilpivirine	C22H18N6	6451164	Major		Inter Info	[13], [14], [15]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[16]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Moderate		Inter Info	[18], [19], [20]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[21]
D0595		Erlotinib	C22H23N3O4	176870	Moderate		Inter Info	[7], [26], [27]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[28]
D0727		Glimepiride	C24H34N4O5S	3476	Moderate		Inter Info	[18], [19], [20]
D0008		Acalabrutinib	C26H23N7O2	71226662	Moderate		Inter Info	[33]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[26], [37]
D0278		Cefditoren	C19H18N6O5S3	9870843	Moderate		Inter Info	[39]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[40], [41], [42]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[40], [41], [42]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Moderate		Inter Info	[43]
D0406		Dabrafenib	C23H20F3N5O2S2	44462760	Moderate		Inter Info	[44], [45], [31]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Moderate		Inter Info	[26], [46]
D0692		Fosamprenavir	C25H36N3O9PS	131536	Moderate		Inter Info	[49]
D0728		Glipizide	C21H27N5O4S	3478	Moderate		Inter Info	[18], [19], [20]
D0730		Glyburide	C23H28ClN3O5S	3488	Moderate		Inter Info	[18], [19], [20]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[50], [51], [52]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[26], [53]
D0898		Ledipasvir	C49H54F2N8O6	67505836	Moderate		Inter Info	[55]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[7], [26], [57]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Moderate		Inter Info	[59]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[60], [61], [62]
D1603		Tolbutamide	C12H18N2O3S	5505	Moderate		Inter Info	[18], [19], [20]
D1686		Velpatasvir	C49H54N8O8	67683363	Moderate		Inter Info	[67]
D1601		Tolazamide	C14H21N3O3S	5503	Moderate		Inter Info	[18], [19], [20]
D0395		Cyanocobalamin	C63H88CoN14O14P	5311498	Minor		Inter Info	[75], [76], [77]
D0539		Duloxetine	C18H19NOS	60835	Minor		Inter Info	[78]
D0236		Calcium carbonate	CCaO3	10112	Minor		Inter Info	[80], [81], [82]
D0483		Didanosine	C10H12N4O3	135398739	Minor		Inter Info	[83], [84]
D0968		Magnesium carbonate	CMgO3	11029	Minor		Inter Info	[80], [81], [82]
D0973		Magnesium hydroxide	H2MgO2	14791	Minor		Inter Info	[80], [81], [82]
D0974		Magnesium oxide	MgO	14792	Minor		Inter Info	[80], [81], [82]
D0989		Mecobalamin	C63H91CoN13O14P	10898559	Minor		Inter Info	[75], [76], [77]
D1313		Ponatinib	C29H27F3N6O	24826799	Minor		Inter Info	[7], [85]
D1328		Prasugrel	C20H20FNO3S	6918456	Minor		Inter Info	[86], [87]
D1377		Raltegravir	C20H21FN6O5	54671008	Minor		Inter Info	[88]
D1701		Vismodegib	C19H14Cl2N2O3S	24776445	Minor		Inter Info	[7], [26], [89]
Affected cellular transport
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0947		Loperamide	C29H33ClN2O2	3955	Major		Inter Info	[1], [2], [3]
D0064		Aminophylline	C16H24N10O4	9433	Moderate		Inter Info	[34], [35], [36]
D0944		Lomitapide	C39H37F6N3O2	9853053	Moderate		Inter Info	[56]
D1570		Theophylline	C7H8N4O2	2153	Moderate		Inter Info	[34], [35], [36]
	CYP450 enzyme induction					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1060		Midazolam	C18H13ClFN3	4192	Moderate		Inter Info	[29], [30], [31]
Affected excretion pathways
	Competitive inhibition of renal tubular secretion					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0576		Entecavir	C12H15N5O3	135398508	Moderate		Inter Info	[25]
D1241		Pemetrexed	C20H21N5O6	135410875	Moderate		Inter Info	[32]
D1343		Procainamide	C13H21N3O	4913	Moderate		Inter Info	[63], [64], [65]
D1656		Trospium	C25H30NO3+	5284632	Moderate		Inter Info	[26], [68], [69]
D1061		Midodrine	C12H18N2O4	4195	Minor		Inter Info	[79]
Pharmacodynamic additive effects
	Increased risk of bradycardia					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[7], [17]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Moderate		Inter Info	[38]
D0661		Fingolimod	C19H33NO2	107970	Moderate		Inter Info	[47], [48]
D0897		Lasmiditan	C19H18F3N3O2	11610526	Moderate		Inter Info	[54]
D1211		Ozanimod	C23H24N4O3	52938427	Moderate		Inter Info	[58]
	Increased risk of hepatotoxicity					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0011		Acetaminophen	C8H9NO2	1983	Minor		Inter Info	[70], [71]
	Increased risk of ventricular arrhythmias					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Moderate		Inter Info	[7], [26], [66]
Pharmacodynamic antagonistic effects
	Antagonize the effect of neuromuscular blocking agents					Drug Num: 8
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0343		Cisatracurium	C53H72N2O12+2	62887	Minor		Inter Info	[72], [73], [74]
D0122		Atracurium	C53H72N2O12+2	47319	Minor		Inter Info	[72], [73], [74]
D0522		Doxacurium	C56H78N2O16+2	60169	Minor		Inter Info	[72], [73], [74]
D1080		Mivacurium	C58H80N2O14+2	5281042	Minor		Inter Info	[72], [73], [74]
D1219		Pancuronium	C35H60N2O4+2	441289	Minor		Inter Info	[72], [73], [74]
D1684		Vecuronium	C34H57N2O4+	39765	Minor		Inter Info	[72], [73], [74]
D1420		Rocuronium	C32H53N2O4+	441290	Minor		Inter Info	[72], [73], [74]
D1510		Succinylcholine	C14H30N2O4+2	5314	Minor		Inter Info	[72], [73], [74]

References
1	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
2	Product Information. Imodium (loperamide). Janssen Pharmaceutica, Titusville, NJ.
3	Tayrouz Y, Ganssmann B, Ding R, et al. "Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement." Clin Pharmacol Ther 70 (2001): 405-14. [PMID: 11719726]
4	Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate 18 (2006): 4. [PMID: 17209238]
5	Ray JE, Marriott D, Bloch MT, McLachlan AJ "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic." Br J Clin Pharmacol 60 (2005): 291-9. [PMID: 16120068]
6	Agarwala S, Persson A, Eley T, et al "Effect of famotidine 20 and 40 mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects".
7	Cerner Multum, Inc. "Australian Product Information.".
8	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
9	Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
10	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
11	van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG "Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective." Lancet Oncol 15 (2014): e315-e326. [PMID: 24988935]
12	Yu G, Zheng QS, Wang DX, Zhou HH, Li GF "Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye." Lancet Oncol 15 (2014): e469-70. [PMID: 25281461]
13	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
14	Product Information. Vemlidy (tenofovir). Gilead Sciences, Foster City, CA.
15	Product Information. Viread (tenofovir). Gilead Sciences, Foster City, CA.
16	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
17	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
18	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
19	Feely J, Collins WCJ, Cullen CM, et al. "Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists." Br J Clin Pharmacol 35 (1993): 321-3. [PMID: 8471413]
20	Kubacka RT, Antal EJ, Juhl RP "The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics." Br J Clin Pharmacol 23 (1987): 743-51. [PMID: 3111514]
21	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
22	Albert KS, Welch RD, DeSante KA, DiSanto AR "Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture." J Pharm Sci 68 (1979): 586-8. [PMID: 435335]
23	Ericsson CD, Feldman S, Pickering LK, Cleary TG "Influence of subsalicylate bismuth on absorption of doxycycline." JAMA 247 (1982): 2266-7. [PMID: 7040708]
24	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
25	Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52. [PMID: 20716581]
28	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
29	Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31. [PMID: 7648762]
30	Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8. [PMID: 7628179]
31	Product Information. Zantac (ranitidine). Glaxo Wellcome, Research Triangle Park, NC.
32	Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
33	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
34	Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
35	Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R "Cimetidine decreases theophylline clearance." Am Rev Respir Dis 123 (1981): 615-7. [PMID: 7023306]
36	Schwartz JI, Bachmann KA, Bond LW, Mahajan VK "Impact of cimetidine on the pharmacokinetics of the theophylline." Clin Pharm 1 (1982): 534-8. [PMID: 7185539]
37	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
39	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
40	Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
41	Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
42	Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
43	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
44	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
45	Product Information. Tafinlar (dabrafenib). GlaxoSmithKline, Research Triangle Park, NC.
46	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
48	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).".
49	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
50	Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
51	Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32. [PMID: 10730911]
52	Product Information. Sporonox (itraconazole). Janssen Pharmaceutica, Titusville, NJ.
53	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
54	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
55	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
56	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
57	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
58	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
59	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
60	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
61	Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66. [PMID: 19075045]
62	Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11. [PMID: 21189337]
63	Martin BK "Effect of ranitidine on procainamide disposition." Br J Clin Pharmacol 19 (1985): 858-60. [PMID: 4027133]
64	Rodvold KA, Paloucek FP, Jung D, Gallastegui J "Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine." Ther Drug Monit 9 (1987): 378-83. [PMID: 2447687]
65	Somogyi A, Bochner F "Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man." Br J Clin Pharmacol 18 (1984): 175-81. [PMID: 6091709]
66	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
67	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
68	Canadian Pharmacists Association "e-CPS."
69	Product Information. Sanctura (trospium chloride). Odyssey Pharmaceutical, East Hanover, NJ.
70	Jack D, Thomas M, Skidmore IF "Ranitidine and paracetamol metabolism." Lancet 2 (1985): 1067. [PMID: 2865542]
71	Rogers SA, Gale KC, Newton JF, et al "Inhibition by ranitidine of acetaminophen conjugation and its possible role in ranitidine potentiation of acetaminophen-induced hepatotoxicity." J Pharmacol Exp Ther 245 (1988): 887-94. [PMID: 3133464]
72	Katende RS, Dimich I "Resistance to nondepolarizing muscle relaxants in a patient treated with ranitidine." Mt Sinai J Med 54 (1987): 330-1. [PMID: 2955219]
73	McCarthy G, Mirakhur RK, Elliott P, Wright J "Effect of H2-receptor antagonist pretreatment on vecuronium- and atracurium-induced neuromuscular block." Br J Anaesth 66 (1991): 713-5. [PMID: 1676594]
74	Woodworth GE, Sears DH, Grove TM, et al "The effect of cimetidine and ranitidine on the duration of action of succinylcholine." Anesth Analg 68 (1989): 295-7. [PMID: 2919769]
75	Dutta SK "Vitamin b-12 malabsorption and omeprazole therapy." J Am Coll Nutr 13 (1994): 544-5. [PMID: 7706583]
76	Lavy NW "Omeprazole and vitamin B12." Ann Intern Med 121 (1994): 74. [PMID: 8198354]
77	Salom IL, Silvis SE, Doscherholmen A "Effect of cimetidine on the absorption of vitamin B12." Scand J Gastroenterol 17 (1982): 129-31. [PMID: 7134827]
78	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
79	Product Information. ProAmatine (midodrine). Roberts Pharmaceutical Corporation, Eatontown, NJ.
80	Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475]
81	Barzaghi N, Gatti G, Crema F, Perucca E "Impaired bioavailability of famotidine given concurrently with a potent antacid." J Clin Pharmacol 29 (1989): 670-2. [PMID: 2569486]
82	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
83	Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH "Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus." Antimicrob Agents Chemother 36 (1992): 2075-9. [PMID: 1444287]
84	Product Information. Videx (didanosine). Bristol-Myers Squibb, Princeton, NJ.
85	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
86	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
87	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
88	Product Information. Isentress (raltegravir). Merck &amp Company Inc, West Point, PA.
89	Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence